More information: Diana G Bohannon et al, CSF1R inhibition depletes brain macrophages and reduces brain virus burden in ...

Niktimvo is a colony-stimulating factor 1 receptor (CSF1R)-targeting monoclonal antibody. It is co-marketed by Incyte and Syndax in the US, with the former having exclusive commercialisation ...

Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM).

Metabolic rewiring is essential for osteoclast differentiation and bone resorption. This study shows that glutaminolysis ...

Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor.

Finally, antibody array profiling of untreated primary GBM tumours showed co-activation of EGFR, MET and PDGFR, as well as RTKs not previously linked with GBM such as RET, MDT1R and CSF1R.

CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. Oncogene. 2020 Jan;40(2):396-407. doi: 10.1038/s41388-020-01536 ...

Presentations related to Seralutinib, an Inhaled PDGFR, CSF1R and c-KIT Inhibitor Session Type: Oral Presentation Session Title: Novel Aspects in Pulmonary Hypertension Session Date & Time ...

Apoe-/-lymphatic vessel endothelial hyaluronic acid receptor 1 Lyve1-Cre)/wt floxed colony-stimulating factor 1 receptor (Csf1r)r flox/flox mice were created through crossbreeding, and some mice ...